← Back to Search

Monoclonal Antibodies

MEDI3506 at dose level 1 for Atopic Dermatitis

Phase 2
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 to 65 years inclusive at the time of consent.
Body mass index between 19.0 and 40.0 kg/m2 inclusive.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 16 and week 24
Awards & highlights

Study Summary

This trial will test if an investigational drug is effective and safe for treating adults with Atopic Dermatitis.

Eligible Conditions
  • Atopic Dermatitis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 16 and week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 16 and week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent Change From Baseline to Week 16 in EASI Score
Secondary outcome measures
Change From Baseline to Week 16 in 5-D Itch
Change From Baseline to Week 16 in DLQI
Change From Baseline to Week 16 in POEM
+24 more

Side effects data

From 2022 Phase 2 trial • 148 Patients • NCT04212169
11%
Dermatitis atopic
5%
Carpal tunnel syndrome
5%
Headache
5%
Hypotension
5%
Urine analysis abnormal
5%
Aphthous ulcer
5%
Presyncope
5%
Nausea
5%
Pruritus
5%
Acarodermatitis
5%
Folliculitis
5%
Gamma-glutamyltransferase increased
5%
Oral herpes
5%
Nasopharyngitis
5%
Liver function test increased
5%
Dermatitis infected
100%
80%
60%
40%
20%
0%
Study treatment Arm
MEDI3506 Dose 1
MEDI3506 Dose 2
MEDI3506 Dose 3
Placebo

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: MEDI3506 at dose level 3Experimental Treatment1 Intervention
Participant will receive multiple doses of MEDI3506 at dose level 3.
Group II: MEDI3506 at dose level 2Experimental Treatment1 Intervention
Participant will receive multiple doses of MEDI3506 at dose level 2.
Group III: MEDI3506 at dose level 1Experimental Treatment1 Intervention
Participant will receive multiple doses of MEDI3506 at dose level 1.
Group IV: PlaceboPlacebo Group1 Intervention
Participant will receive multiple doses of Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MEDI3506
2021
Completed Phase 2
~1270

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,247 Previous Clinical Trials
288,535,330 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
2019. "Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04212169.
~28 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top